Simvastatin has been found to reduce ovarian cancer cell adhesion to peritoneal mesothelial cells through decreased expression of VCAM-1 and β1 integrin in vitro [36], suggesting that simvastatin may provide a novel therapeutic approach to the prevention of peritoneal carcinomatosis. This evidence concerns the gene VCAM1 and ovarian cancer.